Ring Therapeutics Raises $117M in Series B Funding
Summary
Backers included Invus, Altitude Life Science Ventures, Partners Investment, UPMC Enterprises, funds and accounts advised by T. Rowe Price Associates, Inc., among others, alongside Flagship Pioneering. Founded by Flagship Labs in 2017 and led by Dr. Tuyen Ong, CEO, and Avak Kahvejian, Ph.D., Chairman, Ring has built a fully integrated and proprietary vector bioplatform to discover and vectorize anelloviruses to produce programmable medicines. The company has built a platform to harness the unique properties of commensal anelloviruses to generate a wide array of vectors with tissue-specific tropism and the potential ability to be re-dosed. This could lead to gene therapies and nucleic acid medicines that could potentially be given multiple times over the course of a person’s life without causing an adverse immune response. Its Anellovectors™ can be engineered for a broad spectrum of therapeutic modalities and delivered through multiple routes of administration.
Funding
Review available funding amount, funding date, investors, and linked company information related to Ring Therapeutics Raises $117M in Series B Funding in the interactive ISVWorld profile.